AbbVie Bolsters Solid Tumor Portfolio with ImmunoGen Acquisition and ELAHERE® Cancer Therapy

AbbVie has announced its acquisition of ImmunoGen, including its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer. The acquisition will expand AbbVie's solid tumor portfolio and accelerate its entry into the commercial market for ovarian cancer. The transaction is valued at approximately $10.1 billion and is expected to close in mid-2024, subject to regulatory approvals and shareholder approval.